United States v. Clifton Coleman

Court of Appeals for the Seventh Circuit·Decided May 26, 2026·No. 23-2760·Published·Kolar

Opinion

In the

United States Court of Appeals For the Seventh Circuit

No. 23-2760 UNITED STATES OF AMERICA, Plaintiff-Appellee,

v.

CLIFTON COLEMAN, Defendant-Appellant.

Appeal from the United States District Court for the Northern District of Illinois, Eastern Division. No. 1:20-cr-00340 — Mary M. Rowland, Judge.

ARGUED OCTOBER 30, 2025 — DECIDED MAY 26, 2026

Before LEE, PRYOR, and KOLAR, Circuit Judges. KOLAR, Circuit Judge. Between 2019 and 2020, Defendant Clifton Coleman participated in a drug trafficking scheme selling fentanyl-laced heroin in two Chicago drug markets. His role in the scheme was twofold: he supplied the product for the operation, and he provided an apartment for his collaborators to mix and package the product for sale.

2 No. 23-2760

In connection with this scheme, Coleman pled guilty to one count of violating 21 U.S.C. §§ 841 and 846, and was sentenced to a 150-month term of imprisonment. In reaching this sentence, the district court applied two sentencing enhancements . First, the district court determined that Coleman was a leader of the drug scheme, supporting a four-level enhancement under United States Sentencing Guideline (“U.S.S.G.”) § 3B1.1(a) (“the leadership enhancement”). Second, the court concluded that Coleman had maintained an apartment on the west side of Chicago (“the South Albany property”) for the purpose of distributing drugs, supporting a two-level enhancement under U.S.S.G. § 2D1.1(b)(12) (“the drug premises enhancement”).

Coleman now appeals his sentence, asserting that the district court applied the two sentencing enhancements in error. On the leadership enhancement, he argues that the government violated Brady v. Maryland, 373 U.S. 83 (1963), by suppressing recordings of statements made by his co-defendants that would have disproved his status as a leader in the drug scheme. On the drug premises enhancement, he argues that the district court’s finding was inconsistent with our recent decisions in United States v. Ford, 22 F.4th 687 (7th Cir. 2022), United States v. Montgomery, 114 F.4th 847 (7th Cir. 2024) (per curiam), and United States v. Craft, 99 F.4th 407 (7th Cir. 2024).

We disagree on both fronts. The record shows that the government provided Coleman with transcript summaries of the co-defendants’ statements that provided the information Coleman sought to undermine his leadership role. Thus, Coleman cannot establish Brady’s materiality prong for the purposes of the leadership enhancement. The drug premises enhancement is more difficult: Coleman presents a close case

No. 23-2760 3

following our opinions in Ford, Montgomery, and Craft. But the combination of his ownership of the South Albany property, his renting the property with knowledge it would be used as a drug premises, and his level of control over the drug activities taking place there justify the enhancement. We affirm.

I. Background

A. The Offense We present the facts as admitted in Coleman’s plea agreement and unchallenged in the Presentence Report (“PSR”). Coleman’s involvement in the drug trafficking organization (“DTO”) at issue dates back to at least February 2019, the first alleged date of his involvement in supplying products to two open-air drug markets in Chicago. His primary role was to provide heroin to lower-level “managers”: Coleman would make weekly deliveries of heroin to three managers—Rodney Rowsey, Bernard Rowsey, and Tarrence Watson—who would then cut, mix, and package the drugs for distribution. Coleman would make these deliveries to the South Albany property, which he personally owned but rented to Watson for roughly $1,000 per month, and where Watson and the Rowseys would mix the product. Once packaged, the managers passed the product along to “distributors” to sell the product at the drug markets, giving a cut to Coleman and the managers . Between February 2019 and July 2020, Coleman supplied , and the DTO sold, at least 25 kilograms of heroin and 40 grams of fentanyl.

In investigating Coleman’s involvement in the DTO, law enforcement assembled a vast library of wiretapped conversations between the various DTO members, including those between Watson and the Rowseys. These conversations 4 No. 23-2760

revealed that Coleman’s involvement was not limited to supplying product: he also had a say in how the DTO sold the product and managed personnel. For instance:

• In an October 8, 2019 text conversation, Watson explained to the Rowseys that Coleman had unilaterally decided to supply weaker heroin to improve volume and sales.

• In an October 20, 2019 call, Watson relayed a warning from Coleman to another DTO member that if he took “[Coleman’s] money again … you don’t work for him [anymore ].”

• In a November 3, 2019 call, Watson explained that Coleman had overruled his decision to “fire” one of the DTO members.

• In a March 18, 2020 conversation, Watson and Bernard Rowsey discussed cutting and mixing the heroin according to what “[Coleman ] want[s] … [to] do.”

The DTO came to an end in July 2020, when the government charged Coleman, Watson, the Rowseys, and other DTO members with a conspiracy “to knowingly and intentionally possess with intent to distribute and distribute a controlled substance” in violation of §§ 841(a)(1) and 846. Coleman pled guilty to the conspiracy charge in February 2023.

B. Sentencing In the PSR, Probation recommended two offense-based sentencing enhancements. First, it applied the four-level leadership enhancement under U.S.S.G. § 3B1.1(a), relying on the charging documents, Coleman’s plea declaration, and the

No. 23-2760 5

government’s version of the events. In applying this enhancement , Probation also relied on a statement from the FBI case agent relaying that Coleman’s co-defendants had, in post-arrest interviews, identified him as the leader of the DTO. Probation also recommended the two-level drug premises enhancement , concluding that Coleman had “owned the [South Albany] property in Chicago where he met with others to cut and package narcotics, and this was not the defendant’s primary residence.” Applying both enhancements increased Coleman’s recommended offense level from 31 to 37. In addition , the leadership enhancement rendered him ineligible for “safety-valve” relief from the statutory minimum and a further two-level reduction. See 18 U.S.C. § 3553(f); U.S.S.G. §§ 2D1.1(b)(18), 5C1.2. With both enhancements applied, Probation ’s recommended guideline range was 210 to 262 months.

Coleman objected to both enhancements. Regarding the leadership enhancement, Coleman presented summaries of the co-defendants’ post-arrest interviews—in the form of FBI “302” forms provided by the government—which contradicted the FBI case agent’s statement that all of his co-defendants had identified him as the DTO’s leader. Indeed, the FBI 302s revealed that some co-defendants had denied Coleman’s leadership status or made no statement regarding his role in the DTO. While observing that it was “somewhat unusual” that the government had not provided actual recordings of the post-arrest interviews in addition to FBI 302s, Coleman’s counsel did not request access to these recordings or argue that they had been suppressed.

As to the drug premises enhancement, Coleman conceded that he owned the property and had rented it to Watson. But he asserted that Watson maintained total control of the 6 No. 23-2760

property, and that his infrequent visits to the South Albany property were to—as a landlord—perform maintenance or deal with his other tenant. He denied ever participating in the mixing or packaging of drugs at the property.

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Clifton Coleman, (7th Cir. 2026).

United States v. Clifton Coleman (United States v. Clifton Coleman) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Brady v. Maryland
373 U.S. 83 (Supreme Court, 1963)
United States v. Daniel
576 F.3d 772 (Seventh Circuit, 2009)
United States v. Acosta
534 F.3d 574 (Seventh Circuit, 2008)
United States v. Ernest D. Shields
789 F.3d 733 (Seventh Circuit, 2015)
United States v. Acasio Sanchez
810 F.3d 494 (Seventh Circuit, 2016)
United States v. Charles A. Evans
826 F.3d 934 (Seventh Circuit, 2016)
United States v. Marcus Ford
22 F.4th 687 (Seventh Circuit, 2022)
Goudy v. Cummings
922 F.3d 834 (Seventh Circuit, 2019)
United States v. Randy Craft
99 F.4th 407 (Seventh Circuit, 2024)
United States v. Travis Montgomery
114 F.4th 847 (Seventh Circuit, 2024)